Irish Medtech License with Philips: Global Expansion
Head Diagnostics Secures Global License with Philips for HDx Cognition, Ushering in a New Era of Early Cognitive Decline Detection
Table of Contents
Dublin, Ireland – July 17, 2025 – In a significant development poised to reshape the landscape of neurological health, Head Diagnostics, an innovative Irish medtech company based at NovaUCD, has announced an exclusive global licensing agreement with Philips for a cutting-edge digital cognitive assessment platform. This strategic move, effective immediately, will see the platform rebranded as HDx Cognition by Head Diagnostics, marking a pivotal moment in the company’s mission to empower clinicians with advanced tools for early and accurate detection of cognitive decline.
The implications of this partnership are profound, particularly in light of the escalating global challenge posed by cognitive impairment and dementia. As millions worldwide grapple with these conditions, the need for accessible and timely diagnostic solutions has never been more critical. HDx Cognition promises to fill this void, offering a elegant yet user-friendly platform designed to enhance clinicians’ ability to identify cognitive decline at its earliest stages, a period when emerging treatments are frequently enough most effective.
The Urgent Need for Early Cognitive Assessment
Cognitive impairment and dementia represent a growing public health crisis, impacting individuals, families, and healthcare systems on a massive scale. The World Health Organization (WHO) estimates that over 55 million people worldwide live with dementia, a figure projected to rise to 10 million new cases every year. This escalating prevalence underscores the critical unmet need for early and accessible diagnosis.
“As cognitive impairment and dementia continue to affect millions globally, early and accessible diagnosis remains a critical unmet need,” stated David van Zuydam, CEO of Head Diagnostics. ”This partnership with Philips is a testament to our commitment to addressing this challenge head-on. HDx Cognition represents a significant leap forward in our ability to support healthcare professionals in identifying these conditions sooner, thereby improving patient outcomes.”
The urgency of this mission is amplified by the increasing focus from governments and healthcare organizations worldwide on improving early detection of neuro-related diseases. Countries such as the USA, UK, france, Italy, South Korea, and Japan are actively prioritizing initiatives to enhance diagnostic capabilities, recognizing that early intervention is key to managing the progression of these debilitating conditions and improving the quality of life for affected individuals.
The Evolving Landscape of Neurotechnology
The integration of HDx Cognition into Head Diagnostics’ portfolio signifies a strategic expansion into the burgeoning field of neurotechnology. This digital platform is not merely a diagnostic tool; it is indeed a comprehensive solution designed to empower primary care physicians, neurologists, and hospitals. By providing a clinically validated and normed cognitive and mental health testing platform, HDx Cognition equips these professionals with the means to detect cognitive decline and associated mental health conditions with enhanced accuracy and efficiency.
The platform’s digital nature offers several key advantages:
Accessibility: HDx Cognition can be deployed across various clinical settings,from specialized neurology clinics to primary care practices,democratizing access to advanced cognitive assessments.
Standardization: The platform ensures consistent and standardized testing protocols, reducing variability and improving the reliability of results. Data-Driven Insights: It generates detailed, objective data that can aid clinicians in making more informed diagnostic decisions and tracking patient progress over time.
Efficiency: The digital format streamlines the assessment process,saving valuable time for both clinicians and patients.
HDx Cognition: A Clinically Validated solution
The core of this new offering, HDx Cognition, is built upon a foundation of rigorous scientific validation and normative data. This ensures that the assessments are not only accurate but also culturally and demographically relevant, allowing for reliable comparisons across diverse patient populations.
Key Features and Benefits of hdx cognition
HDx Cognition is engineered to provide a multifaceted approach to cognitive assessment, addressing various domains crucial for identifying early signs of decline. Its key features and benefits include:
Comprehensive Cognitive Domain Assessment: The platform typically evaluates a range of cognitive functions, including memory (short-term and long-term), attention, executive functions (planning, problem-solving, decision-making), language, and visuospatial abilities. This holistic approach is vital for detecting subtle deficits that might be missed by single-domain tests.
User-Friendly Interface for Clinicians and Patients: Designed with both the healthcare provider and the patient in mind, HDx Cognition offers an intuitive interface. This ease of use is paramount for ensuring patient engagement and minimizing the burden on clinical staff.
Objective and Quantifiable Data: Unlike conventional subjective assessments, HDx Cognition provides objective, quantifiable data. This allows for precise measurement of cognitive performance, enabling clinicians to track changes over time and assess the impact of interventions.
Early Detection Capabilities: The platform is specifically designed to identify the earliest indicators of cognitive impairment